RT Journal Article
T1 Bromelain-based enzymatic burn debridement: Spanish multidisciplinary consensus.
A1 Serracanta, Jordi
A1 Baena, Jacinto
A1 Martinez-Mendez, José R
A1 Sanchez-Sanchez, Manuel
A1 Lopez-Suso, Eugenia
A1 Galeiras, Rita
A1 Perez-Del-Caz, Maria Dolores
A1 Vivo-Benlloch, Carmen
A1 Monclus-Fuertes, Enrique
A1 Casalduero-Viu, Jacobo
A1 Martin-Playa, Patricia
A1 Ugalde-Gutierrez, Marta
A1 Gacto-Sanchez, Purificacion
A1 Rincon-Ferrari, Maria Dolores
A1 Piqueras-Perez, Jose Maria
A1 Martin-Luengo, Ana
K1 Bromelain
K1 Burn wound
K1 Consensus
K1 Delphi
K1 Dermis preservation
K1 Enzymatic debridement
K1 NexoBrid®
AB Bromelain-based enzymatic debridement is gaining increased interest from burn specialists in the last few years. The objective of this manuscript is to update the previous, first Spanish consensus document from 2017 (Martínez-Méndez et al. 43:193-202, 2017), on the use of enzymatic debridement with NexoBrid® in burn injuries, adding the clinical experience of a larger panel of experts, integrating plastic surgeons, intensivists, and anesthesiologists. A consensus guideline was established by following a modified Delphi methodology of a 38-topic survey in two rounds of participation. Items were grouped in six domains: general indication, indication in critical patients, pain management, conditions for NexoBrid® application, NexoBrid® application technique, and post-debridement wound care. In the first round, experts established consensus (strongly agree or agree) on 13 of the 38 statements. After the second round, a consensus was reached on 24 of the 25 remaining statements (97.2%). The present updated consensus document provides recommendations on the use of bromelain-based enzymatic debridement NexoBrid®, integrating the extensive clinical experience of plastic surgeons, intensivists, and anesthesiologists in Spain. Further clinical trials and studies are required to corroborate, modify, or fine tune the current statements.
SN 0930-343X
YR 2022
FD 2022-09-29
LK http://hdl.handle.net/10668/19686
UL http://hdl.handle.net/10668/19686
LA en
DS RISalud
RD Apr 18, 2025